粪便微生物群移植治疗复发性艰难梭菌感染：澳大利亚的经验——有效、安全，但仍有改进空间。

Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement.

机构信息

Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.

Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2021 Jan;51(1):106-110. doi: 10.1111/imj.15162.

DOI:10.1111/imj.15162

PMID:33572016

Abstract

Faecal microbiota transplantation (FMT) is reportedly effective and safe for the management of recurrent or refractory Clostridioides difficile infection (CDI), yet real-world data of outcomes of FMT in Australia are limited. In this series, FMT safely resulted in resolution of CDI in 19 patients with reduced healthcare utilisation after 25 FMT, but one patient was diagnosed with an anti-nuclear antibody-positive constitutional illness and Hashimoto thyroiditis following FMT. Further prospective evaluation of the utility of FMT earlier in CDI treatment algorithms to minimise cost and morbidity, and recipient follow up for immune-mediated conditions, is required.

摘要

据报道，粪便微生物群移植（FMT）对于复发性或难治性艰难梭菌感染（CDI）的治疗是有效且安全的，但澳大利亚 FMT 结果的实际数据有限。在本系列中，25 次 FMT 后，19 名患者的 CDI 得到安全缓解，减少了医疗保健的使用，但 1 名患者在 FMT 后被诊断出患有抗核抗体阳性的全身性疾病和桥本甲状腺炎。需要进一步前瞻性评估 FMT 在 CDI 治疗方案中的早期应用，以降低成本和发病率，并对接受者进行免疫介导疾病的随访。